Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report

By afschroeder • October 24, 2025

Le X, Baik C, Cho BC, Riess JW, Piotrowska Z, Johannes de Langen A, Goldberg SB, Goldman JW, Reguart N, Shiraishi Y, Ambrose H, Fraenkel PG, Ruiz BM, Smith PE, Tang KH, Yu HA. Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report. J Thorac Oncol. 2025 Oct 21:S1556-0864(25)02856-4. doi: 10.1016/j.jtho.2025.10.009. Epub ahead of print. PMID: 41130408.

Tags: Cardiology/Epi, EGFR, MET (min 3), NSCLC, Osimertinib, Publications, Savolitinib (max 5)

Median Survival Among Patients Hospitalized for Heart Failure with Reduced Ejection Fraction Prescribed Quadruple Medical Therapy

Greene SJ, Xu H, Chiswell K, Felker GM, Lewsey SC, Divanji PH, Goertz HP, Heitner SB, Butler J, Fonarow GC. Median Survival Among Patients Hospitalized[...]

Adult congenital cardiac interventional training, competencies, and organization. A Statement of the ESC ACHD Working Group, the EAPCI, the AEPC, and the PICS-Society

Chessa M, Brida M, Budts W, Chieffo A, Dua J, Kaleschke G, Kempny A, Kenny D, Krasemann T, Rahbek Schmidt M, Aboulhosn J. Adult congenital[...]

Comprehensive macroscopic living anatomy of the swine heart: comparative visual approach with virtual dissection

Rios KP, Moussa AM, Rios HA, Rimmer M, Miyazaki Y, Aoyama D, Aladham RN, Defelice LG, Hanna P, Hayase JH, Chung WH, Xu S, Ajijola[...]